Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Minerva Neurosciences ( (NERV) ) has issued an update.
Minerva Neurosciences announced that at a virtual key opinion leader event held on February 3, 2026, it would provide additional details on its proposed confirmatory Phase 3 trial of roluperidone for the treatment of negative symptoms in schizophrenia. The company outlined plans to initiate the trial in the second quarter of 2026, enrolling 380 patients randomized to receive either placebo or a once-daily 64 mg dose of roluperidone, with a primary efficacy endpoint based on change from baseline in PANSS Marder negative symptoms factor score at 12 weeks, followed by a 40-week relapse assessment phase in which patients will crossover to receive either roluperidone or antipsychotics, with topline efficacy data expected in the second half of 2027 and relapse assessment results anticipated in the second half of 2028, underscoring Minerva’s continued effort to advance a potential first-in-class treatment for an area of significant unmet need in schizophrenia care.
The most recent analyst rating on (NERV) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Minerva Neurosciences stock, see the NERV Stock Forecast page.
Spark’s Take on NERV Stock
According to Spark, TipRanks’ AI Analyst, NERV is a Neutral.
The score is held back primarily by weak financial fundamentals (ongoing losses, sustained cash burn, and negative equity). Technicals are moderately supportive with price above key moving averages and positive MACD, while corporate events add support via improved financing capacity (though with dilution risk). Valuation is constrained by negative earnings and no dividend support.
To see Spark’s full report on NERV stock, click here.
More about Minerva Neurosciences
Minerva Neurosciences, Inc. is a biopharmaceutical company focused on developing therapies for central nervous system disorders, with a key program centered on roluperidone, an investigational treatment targeting negative symptoms associated with schizophrenia.
Average Trading Volume: 69,822
Technical Sentiment Signal: Buy
Current Market Cap: $175.7M
See more data about NERV stock on TipRanks’ Stock Analysis page.